CASI Pharmaceuticals (CASIF) Cash & Equivalents (2021 - 2025)

CASI Pharmaceuticals (CASIF) has 5 years of Cash & Equivalents data on file, last reported at $5.6 million in Q4 2025.

• Quarterly Cash & Equivalents fell 58.42% year-over-year to $5.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.6 million (down 58.42% YoY) and the FY2025 annual result came in at $5.6 million, down 58.42% from the prior year.
• Cash & Equivalents advanced to $5.6 million in Q4 2025, from $4.7 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $47.1 million in Q4 2022 to a low of $9533.0 in Q2 2024.
• A 5-year average of $13.5 million and a median of $9.5 million in 2024 frame the typical range for Cash & Equivalents.
• The widest YoY moves for Cash & Equivalents: up 70601.77% in 2025, down 99.91% in 2025.
• Tracing CASIF's Cash & Equivalents over 5 years: stood at $38.7 million in 2021, then gained by 21.72% to $47.1 million in 2022, then tumbled by 63.74% to $17.1 million in 2023, then declined by 21.16% to $13.5 million in 2024, then slumped by 58.42% to $5.6 million in 2025.
• The last three Cash & Equivalents figures came in at $5.6 million (Q4 2025), $4.7 million (Q3 2025), and $6.7 million (Q2 2025), per Business Quant data.